Please ensure Javascript is enabled for purposes of website accessibility

Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know

By Keith Speights - Jul 31, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker delivered its first-ever quarterly profit and trounced Wall Street top- and bottom-line estimates.

Ironwood Pharmaceuticals (IRWD 1.08%) shareholders couldn't have been happy campers when the drugmaker reported its quarterly results in May. The company announced that revenue dropped by 0.6% from the prior-year period while its bottom line deteriorated significantly.

Any questions investors had about Ironwood's second quarter were answered when the company announced its Q2 results after the market closed on Tuesday. Here's what you need to know from Ironwood's quarterly update.

Woman holding a drawing of a smiling colon while giving a thumbs up.

Image source: Getty Images.

By the numbers

Ironwood's top-line performance improved dramatically in the second quarter. Revenue jumped 26% year over year to $102.2 million, handily topping the average analysts' Q2 revenue estimate of $89.62 million.

How did Ironwood's bottom line look in the second quarter? Much better. The company reported net income of $12.3 million, or $0.08 per share, on a generally accepted accounting principles (GAAP) basis, compared with a loss of $49.4 million, or a loss of $0.32 per share, in the same period in 2018. It marked Ironwood's first quarter to record a profit.

On a non-GAAP adjusted basis, Ironwood's net income in the second quarter was $16 million, or $0.10 per share. This reflected a huge improvement from the prior-year period adjusted net loss of $32.9 million, or $0.22 per share. Wall Street analysts estimated that Ironwood would post a net loss of $0.03 per share in the quarter.

Behind the numbers

You can sum up the reason behind Ironwood's tremendous improvement in Q2 in one word: Linzess. Ironwood splits the U.S. profits on the gastrointestinal-disorder drug with its partner, Allergan. In the second quarter, Ironwood posted collaboration revenue of $75 million related to sales of Linzess, up from $69 million in the prior-year period.

Ironwood's partner for Linzess in Japan is Astellas Pharma. Japanese sales of the drug generated $24.9 million in revenue for Ironwood in Q2, up a whopping 183% year over year.

The company's expenses decreased by 38% to $80.6 million in the second quarter. The decline was driven, in part, by a significant decrease in restructuring expenses and a $3.2 million gain on lease modification.

In addition to reporting great financial results in Q2, Ironwood also announced that it will soon have a new home. The company said in June that it plans to relocate its headquarters to a new office in downtown Boston. Ironwood currently is based in Cambridge, Massachusetts. The move should be completed in the fourth quarter of this year. Ironwood expects to save more than $25 million over the next five years as a result of the relocation.

Looking ahead

Ironwood reaffirmed its full-year 2019 guidance provided previously. The company still expects that 2019 revenue will be between $370 million and $390 million.

More good news could be on the way for Ironwood. The company expects to launch Linzess in China in the second half of this year along with its partner, AstraZeneca.

Ironwood and Allergan reported positive results in June from a late-stage clinical study evaluating Linzess on helping with bloating, pain, and discomfort in adult patients with irritable bowel syndrome with constipation. The companies have already started sharing the additional benefits identified in this study with healthcare professionals. Over the longer term, Ironwood anticipates reporting key data readouts from non-opioid pain reliever MD-7246 and acid reflux drug IW-3718 next year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ironwood Pharmaceuticals, Inc. Stock Quote
Ironwood Pharmaceuticals, Inc.
IRWD
$11.19 (1.08%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.